Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN);Traitement de la dysfonction érectile par les inhibiteurs de la phosphodiestérase-5 et troubles oculaires par neuropathie optique ischémique antérieure non artéritique (NOIAN)

Progres en Urologie

Volumn 17, Issue 5, 2007, Pages 920-927

  Calvet, Cyril ^a   Martin, Karin ^a,b,c   Robert, Grégoire ^a   Moore, Nicholas ^a,b,c   Eftekhari, Pirayeh ^d   Farghal, Houssam ^a   Molimard, Mathieu ^a,b,c   Ballanger, Philippe ^a  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM U657   (France)

^d HÔPITAL FERNAND WIDAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE; TADALAFIL;

ARTICLE; BIOPSY; DRUG ANTAGONISM; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; UNITED STATES;

BIOPSY; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 35348950642     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(07)92389-1     Document Type: Short Survey

References (67)

1. DE BOER B.J., ET AL.: Erectile dysfunction in primary care: prevalence and patient characteristics. The ENIGMA study. Int. J. Impot Res., 2004; 16: 358-364.
2. MOREIRA E.D. JR., ET AL.: Prevalence and correlates of erectile dysfunction: results of the Brazilian study of sexual behavior. Urology, 2001; 58: 583-588.
3. GIULIANO F., ET AL.: Prevalence of erectile dysfunction in France: results of an epidemiological survey of a representative sample of 1004 men. Eur. Urol., 2002; 42: 382-389.
4. GIULIANO F., ET AL.: Prevalence of erectile dysfunction in France: results of an epidemiological survey conducted on a representative sample of 1004 men. Prog. Urol., 2002; 12: 260-267.
5. COSTA P., AVANCES C., WAGNER L.: Erectile dysfunction: knowledge, wishes and attitudes. Results of a French study of 5.099 men. Prog. Urol., 2003; 13: 85-91.
6. BOOLELL M., ET AL.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot Res., 1996; 8: 47-52.
7. http://www.emea.europa.eu/htms/human/epar/eparintro.htm
8. BEAVO J.A.: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 1995; 75: 725-748.
9. BISCHOFF E.: Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot Res., 2004; 16: 11-14.
10. MARMOR M.F., KESSLER R.: Sildenafil (Viagra) and ophthalmology. Surv. Ophthalmol., 1999; 44: 153-162.
11. DE ROSE A.F., GALLO F., CARMIGNANI G.: Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. Int. J. Impot Res., 2005; 17: 76-79.
12. DRYJA T.P., ET AL.: Frequency of mutations in the gene encoding the alpha subunit rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa. Invest. Ophthalmol., Vis. Sci., 1999; 40: 859-865.
13. www.ncbi.nlm.nih.gov/pubmed.
14. BOLLINGER K., LEE M.S.: Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch. Ophthalmol., 2005; 123: 400-401.
15. BOSHIER A., PAMBAKIAN N., SHAKIR S.A.: A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil. Int. J. Clin. Pharmacol. Ther., 2002; 40: 422-423.
16. POMERANZ H.D., ET AL.: Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology, 2002; 109: 584-587.
17. POMERANZ, H.D., BHAVSAR A.R.: Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J. Neuroophthalmol., 2005; 25: 9-13.
18. GRUHN N., FLEDELIUS H.C.: Unilateral optic neuropathy associated with sildenafil intake. Acta Ophthalmol. Scand., 2005; 83: 131-132.
19. ESCARAVAGE G.K., JR., WRIGHT J.D. JR., GIVRE S.J.: Tadalafil associated with anterior ischemic optic neuropathy. Arch. Ophthalmol., 2005; 123: 399-400.
20. EGAN R., POMERANZ H.: Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch. Ophthalmol., 2000; 118: 291-292.
21. DHEER S., REKHI G.S., MERLYN S.: Sildenafil associated anterior ischaemic optic neuropathy. J. Assoc. Physicians India, 2002; 50: 265.
22. CUNNINGHAM A.V., SMITH K.H.: Anterior ischemic optic neuropathy associated with viagra. J. Neuroophthalmol., 2001; 21: 22-25.
23. AKASH R., ET AL.: Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra. J. Ocul. Pharmacol. Ther., 2005; 21: 315-317.
24. PETER N.M., SINGH M.V., FOX P.D.: Tadalafil-associated anterior ischaemic optic neuropathy. Eye, 2005; 19: 715-717.
25. HAYREH S.: Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology, 1987; 94: 1488-1502.
26. HAYREH S.: Anterior ischemic optic neuropathy. Arch. Neurol., 1981; 182:29-41.
27. JOHNSON L.N., ARNOLD A.C.: Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in state of missouri and los angeles county, California. J. Neuroophthalmol., 1994 ; 14: 38-44.
28. HATTENHAUER M.G., ET AL.: Incidence of nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol., 1997; 123: 103-107.
29. BERI M., ET AL.: Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. Ophthalmology, 1987; 94: 1020-1028.
30. DERAMO V., ET AL.: Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology, 2003; 110: 1041-1046.
31. ELLENBERGER C.: Ischemic optic neuropathy as a possible early complication of vascular hypertension. Am. J. Ophthalmol., 1979; 88: 1045-1051.
32. HAYREH S., SERVAIS G., VIRDI P.: Fundus lesions in malignant hypertension. V. Hypertensive optic neuropathy. Ophthalmology, 1986; 93: 74-87.
33. HAYREH S.S.: Effect of nocturnal blood pressure reduction on retrobulbar hemodynamics in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol., 2002; 240: 867-868.
34. MCGWIN G.J., ET AL.: Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br. J. Ophthalmol., 2006; 90: 154-157.
35. HAYREH S., ET AL.: Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol., 1994; 118: 766-780.
36. HAYREH S.: Anterior ischemic optic neuropathy. IV. Occurrence after cataract extraction. Arch. Ophthalmol., 1980; 98: 1410-1416.
37. BECK R.W., SERVAIS G.E., HAYREH S.S.: Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology, 1987; 94: 1503-1508.
38. BURDE R.M.: Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol., 1993; 116: 759-764.
39. SALOMON O., ET AL.: Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye, 1999. 13: 357-359.
40. BECK R.W., ET AL.: Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol., 1997; 123: 212-217.
41. MOORE N., ET AL.: Adverse drug reaction monitoring: doing it the French way. Lancet, 1985; 2: 1056-1058. 42. HAYREH S.S.: Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship ? J. Neuroophthalmol., 2005; 25: 295-298.
42. HAYREH S.S., ET AL.: Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am. J. Ophthalmol., 1994; 117: 603-624.
43. PACHE M., ET AL.: Sildenafil induces retinal vasodilatation in healthy subjects. Br. J. Ophthalmol., 2002; 86: 156-158.
44. KOKSAL M., ET AL.: The effects of sildenafil on ocular blood flow. Acta Ophthalmol Scand, 2005; 83: 355-359.
45. PARIS G., ET AL.: Sildenafil increases ocular perfusion. Int. Ophthalmol., 2001; 23: 355-358.
46. GRUNWALD J.E., ET AL.: Effect of sildenafil citrate (Viagra) on the ocular circulation. Am. J. Ophthalmol., 2001; 131: 751-755.
47. HAYREH S.: Blood flow in the optic nerve head and factors that may influence it. Prog. Retin. Eye Res., 2001; 20: 595-624.
48. GANDHI J.S.: Sildenafil-associated NAION. Ophthalmology, 2003; 110: 1860-1861.
49. PADMA-NATHAN H., ET AL.: A 4-year update on the safety of sildenafil citrate (Viagra). Urology, 2002; 60: 67-90.
50. MCLEOD D., MARSHALL J., AND KOHNER E.: Role of axoplasmic transport in the pathophysiology of ischaemic disc swelling. Br. J. Ophthalmol, 1980; 64:247-261.
51. EL-SAKKA A.I., ET AL.: Coronary artery risk factors in patients with erectile dysfunction. J. Urol., 2004; 172: 251-254.
52. KIM S.: Hyperlipidemia and erectile dysfunction. Asian J. Androl., 2000; 2: 161-166.
53. MIRONE V, ET AL.: Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur. Urol., 2002; 41:294-297.
54. ROUMEGUERE T., ET AL.: Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur. Urol., 2003; 44: 355-359.
55. MONTORSI P., MONTORSI F., SCHULMAN C.: Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder ? Eur. Urol., 2003; 44: 352-354.
56. COSTA P., ET AL.: Erectile dysfunction: a sentinel symptom. Prog. Urol., 2005; 15: 203-207.
57. BONDIL P., DELMAS V.: "Penis angina" or the current revolution in erectile dysfunction (ED). Prog. Urol., 2005; 15: 1030-1034.
58. BIVALACQUA T.J., ET AL.: Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J. Androl., 2003; 24: 17-37.
59. SOLOMON H., MAN J.W., JACKSON G.: Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart., 2003; 89: 251-253.
60. SPEEL T.G., VAN LANGEN H., MEULEMAN E.J.: The risk of coronary heart disease in men with erectile dysfunction. Eur. Urol., 2003; 44: 366-370.
61. KIRBY M. ET AL.: Is erectile dysfunction a marker for cardiovascular disease ? Int. J. Clin. Pract., 2001; 55: 614-618.
62. CHEITLIN M.D.: Erectile dysfunction: the earliest sign of generalized vascular disease ? J. Am. Coll. Cardiol., 2004; 43: 185-186.
63. BURCHARDT M., ET AL.: Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension. Int. J. Impot Res., 2001; 13: 276-281.
64. O'KANE P.D., JACKSON G. Erectile dysfunction: is there silent obstructive coronary artery disease ? Int. J. Clin. Pract., 2001; 55: 219-220.
65. HAEFLIGER I., ET AL.: The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology ? Surv. Ophthalmol., 1994; 39: 123-132.
66. FDA. Updates labeling for erectile dysfunction drugs. FDA consum, 2005; 39:3.
67. VIAGRA'S APPROVED LABEL.: http://www.fda.gov/cder/consumerinfo/druginfo/ Viagra.HTM.